Immucor CE marks HEA BeadChip for blood testing

 
• By Madeleine Armstrong

Immucor has CE marked its Human Erythrocyte Antigen (HEA) BeadChip kit. The product is designed for DNA testing of blood before transfusion, which the firm believes will improve matching of patient and donor blood, and therefore safety. The HEA BeadChip uses multiplex DNA analysis to perform extended typing of 32 red blood cell antigens simultaneously. The assay was originally developed by BioArray, which Norcross, Georgia-based Immucor acquired in 2008. The company has already CE marked its Human Platelet Antigen (HPA) assay, which is used for platelet genotyping, and the Array Imaging System, to read and interpret test results.

Immucor has CE marked its Human Erythrocyte Antigen (HEA) BeadChip kit. The product is designed for DNA testing of blood before transfusion, which the firm believes will improve matching of patient and donor blood, and therefore safety. The HEA BeadChip uses multiplex DNA analysis to perform extended typing of 32 red blood cell antigens simultaneously. The assay was originally developed by BioArray, which Norcross, Georgia-based Immucor acquired in 2008. The company has already CE marked its Human Platelet Antigen (HPA) assay, which is used for platelet genotyping, and the Array Imaging System, to read and interpret test results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

EU Pilot Features ‘All-In-One’ Regulatory Path For Drug/Diagnostic Trials

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By Ashley Yeo

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.